Volume 6, Issue 1 August 2012
We have previously communicated on the increased risk of myopathy associated with use of high-dose simvastatin (80 mg daily) – see Drug Safety Update May 2010.
Considering the risk of myopathy associated with simvastatin, recent analysis of clinical trial data, spontaneously reported cases and drug- drug interaction studies has resulted in further changes to the simvastatin prescribing information.
The changes include contraindications to concomitant use with certain medicines and maximum dose recommendations when simvastatin is taken with a number of other medicines, as these interactions may increase plasma concentrations of simvastatin which is associated with an increased risk of myopathy and/or rhabdomyolysis. Key points to note are that:
A full updated listing of all the interactions is provided in the table below.
Drug interactions associated with increased risk of myopathy/rhabdomyolysis
|Interacting agents||Prescribing recommendations|
HIV protease inhibitors (eg, nelfinavir)
|Contraindicated with simvastatin|
|Other fibrates (except fenofibrate)||Do not exceed 10 mg simvastatin daily|
|Do not exceed 20 mg simvastatin daily|
|Fusidic acid||Patients should be closely monitored. Temporary suspension of simvastatin treatment may be considered.|
|Grapefruit juice||Avoid grapefruit juice when taking simvastatin|
BNF section 2.12: Lipid-regulating drugs
Article citation: Drug Safety Update August 2012, vol 6, issue 1: S1